XTX Topco Ltd Has $95,000 Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

XTX Topco Ltd lifted its stake in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 51.2% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 49,290 shares of the company’s stock after buying an additional 16,687 shares during the quarter. XTX Topco Ltd’s holdings in Tenaya Therapeutics were worth $95,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. SG Americas Securities LLC bought a new position in Tenaya Therapeutics in the 3rd quarter valued at about $49,000. The Manufacturers Life Insurance Company grew its position in shares of Tenaya Therapeutics by 43.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after purchasing an additional 7,000 shares during the last quarter. Algert Global LLC bought a new position in shares of Tenaya Therapeutics during the second quarter worth approximately $74,000. Walleye Capital LLC acquired a new stake in Tenaya Therapeutics during the 3rd quarter worth approximately $134,000. Finally, Panagora Asset Management Inc. bought a new stake in Tenaya Therapeutics in the 2nd quarter valued at $164,000. Institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Stock Up 18.4 %

TNYA stock opened at $1.67 on Friday. The company’s 50-day moving average price is $2.43 and its two-hundred day moving average price is $2.69. The firm has a market cap of $132.30 million, a P/E ratio of -1.16 and a beta of 2.72. Tenaya Therapeutics, Inc. has a 12 month low of $0.99 and a 12 month high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. Equities analysts predict that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on TNYA shares. Canaccord Genuity Group reiterated a “buy” rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research report on Wednesday. Piper Sandler reissued an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reaffirmed a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a report on Wednesday. Finally, Leerink Partners reiterated an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tenaya Therapeutics currently has an average rating of “Buy” and a consensus price target of $17.33.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.